|Articles|April 15, 2002
PDT trials aim to extend knowledge from TAP, VIP studies
Baltimore-Ocular photodynamic therapy (PDT) using verteporfin (Visudyne, Novartis) already has been shown to be beneficial in the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) in age-related macular degeneration (AMD).
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Spotlight on women's health: Understanding thyroid eye disease
2
FDA extends Aldeyra's reproxalap PDUFA after requesting additional clinical study report
3
NCX 470 advances toward US, China NDA submissions for NCX 470
4
Malar edema: Perspectives from plastic surgery and ophthalmology
5




































